Document:

Form of First Amendment

 EXHIBIT 10.62 
 FIRST AMENDMENT TO 
 EMPLOYMENT AGREEMENT 
 THIS FIRST AMENDMENT TO EMPLOYMENT AGREEMENT (the “Amendment”) is made and entered into on this      day of June
2008 (the “Effective Date”), by and between Salix Pharmaceuticals, Ltd., a Delaware corporation, having an office at 1700 Perimeter Park Drive, Morrisville, North Carolina 27560-8404 (together with its subsidiaries, affiliates and
successors hereafter referred to as “Employer”), and
                                        ,
an individual residing at
                                         
    (“Employee”). 
 WITNESSETH: 
 WHEREAS, the Employer and Employee entered into an Employment Agreement dated as of
            ,          (the “Employment Agreement”); 
 WHEREAS, Section 7.9 of the Employment Agreement permits modification in a writing signed by both parties to the Employment Agreement; 

WHEREAS, the parties hereto now desire to amend the Employment Agreement upon the terms and conditions enumerated below; and 
 NOW, THEREFORE, in consideration of the foregoing, the mutual promises herein contained, and other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, hereby agree as follows. 
 1. The Appendix
“B” Schedule of Severance Benefits is hereby amended as follows. 
 (a) Section A is hereby amended by deleting the first sentence
and inserting the following sentence. 
 “In the event that the provisions of Paragraph 6.4 of this Agreement apply, then in addition to
any other benefits payable under this Agreement the Employer shall provide to the Employee the severance benefits set forth below.” 
 (b) Section B is hereby is hereby amended by inserting the following sentence at the end of the first paragraph. 
 “The
Employer shall provide to Employee the severance benefits described in Paragraph C below commencing on termination of the Employee’s employment with Employer or termination of this Agreement that qualifies under the terms of Paragraph 6.4 of
this Agreement for severance benefits and that occurs within 12 months of a Change in 

 
Control (as defined in Section 7.4 of the Agreement), with such severance benefits for a period of
                     from the termination date with respect to Base Salary and
                     with respect to Bonus (such period being the “Benefit Period” in such circumstances).” 

2. Effect of Amendment. Terms used in this Amendment and not expressly defined herein shall have the same meaning as assigned to them in the
Employment Agreement. Except as expressly amended herein, the terms of the Employment Agreement are incorporated herein by reference as if fully set out and shall remain in full force and effect in accordance with their terms. Employee expressly
agrees and acknowledges that any and all of his post-termination obligations under the Employment Agreement (including but not limited to the confidentiality provisions and restrictive covenants set out in Articles IV and V of the Employment
Agreement) remain in full force and effect. 
 3. Waiver. No waiver of any provision of this Amendment shall be valid unless the same
is in writing and signed by the party against whom such waiver is sought to be enforced. Failure to insist upon strict compliance with any of the terms, covenants or conditions hereof shall not be deemed a waiver of such terms, covenants or
conditions, nor shall any waiver or relinquishment of any right or power granted hereunder at any particular time be deemed a waiver or relinquishment of such rights or power at any other time or times. 
 4. Severability. The provisions of this Amendment shall be deemed severable, and the invalidity or unenforceability of any provision (or part
thereof) hereof shall in no way affect the validity or enforceability of any other provision (or remaining part thereof). 
 5. Governing
Law. This Amendment shall be governed, construed and interpreted in accordance with the laws of the State of North Carolina, without giving effect to principles of conflicts of laws. 
 6. Binding Effect. This Amendment shall be binding upon and shall inure to the benefit of the parties hereto and their heirs, successors and
assigns. 
 7. Entire Agreement. This Amendment and the Employment Agreement contain the entire agreement and understandings by and
between Employer and Employee with respect to the covenants herein described, and no representations, promises, agreements or understandings, written or oral, not herein contained shall be of any force or effect. No change or modification hereof
shall be valid or binding unless the same is in writing and signed by the parties hereto. 
 8. Counterparts. This Amendment may be
executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 
 [The next page is the signature page.] 

 IN WITNESS WHEREOF, the parties have executed this Amendment to the Employment Agreement, effective as of
the Effective Date. 
  

			
	EMPLOYER:
	
	SALIX PHARMACEUTICALS, LTD.
		
	By:	 	 /s/ Richard A. Franco, Sr.

		 	Richard A. Franco, Sr.
		 	 Chairman of the Compensation Committee of the Board of Directors

	
	EMPLOYEE:
	
	  

	(Signature)
	
	  

	(Print or Type Name)Form of Subscription Agreement

 Exhibit 10.1 
 UNIDYM, INC. 
 SUBSCRIPTION AGREEMENT 
 SERIES C PREFERRED STOCK 

 SUBSCRIPTION AGREEMENT 
 THIS SUBSCRIPTION AGREEMENT (this “Agreement”) is made as of the last date indicated on the signature pages hereto between
Unidym, Inc., a Delaware corporation (the “Company”), and the undersigned investor party hereto (“Investor”). 
 RECITALS 
 WHEREAS, the Company wishes to sell up to an aggregate of 8,333,333 shares of the
Company’s Series C Preferred Stock (“Shares”) to one or more investors at a purchase price of $1.80 per Share, and the Investor wishes to purchase Shares from the Company. 
 NOW, THEREFORE, in consideration of the mutual covenants, agreements and conditions, and upon acknowledgement of each of the parties of the receipt of
valuable consideration, the parties herein agree as follows: 
 1. Purchase and Sale of Shares. 
 1.1 The Closing. At the Closing (as defined below), the Company shall issue and sell to Investor such number of Shares as is set forth immediately
below Investor’s name on the signature pages hereto. Investor shall pay an amount equal to $1.80 times the number of Shares to be purchased by the Investor (the “Purchase Price”) in cash (by check or wire transfer) or by
cancellation of indebtnedness in United States Dollars to the Company to be held in escrow until the Closing, for release to the Company thereafter. Promptly after the Closing, the Company shall deliver to Investor a duly executed certificate
representing the Shares which Investor is purchasing hereunder. The purchase and sale transaction contemplated hereby will close on the first business day immediately following the satisfaction of the Closing conditions set forth herein, which is
targeted to be no later than 5:00 p.m., Pacific Time on June 6, 2008, as such date and time may be modified by the Company in its sole discretion (such day, the “Closing”). 
 1.2 Additional Closing(s). 
 (a)
Conditions of Additional Closing(s). At any time and from time to time following the Closing, the Company may, at one or more additional closings (each an “Additional Closing”), without obtaining the signature, consent
or permission of Investor, offer and sell to other investors (the “New Investors”), at a price of $1.80 per Share, up to that number of Shares that is equal to 8,333,333 Shares less the number of Shares previously issued and
sold by the Company. New Investors may include persons or entities who are already owners of shares of the Company’s Series C Preferred Stock or other capital stock. 
 (b) Amendments. The Company and the New Investors purchasing Shares at each Additional Closing will execute a Subscription Agreement in
substantially the same form hereof, and the New Investors will, to the extent not already a party thereto, execute counterpart signature pages to: (i) the Amended and Restated Investors’ Rights Agreement in the form attached to this
Agreement as Exhibit A (the “Investors’ Rights Agreement”), (ii) the Amended and Restated Right of First Refusal and Co-Sale Agreement in the form attached to this Agreement as Exhibit B (the
“ROFR Agreement”), and (iii) the Amended and Restated Voting Agreement in the form attached to this Agreement as Exhibit C (the “Voting Agreement”) (the Investors’ Rights Agreement,
ROFR Agreement and Voting Agreement, collectively, the “Related Agreements”). Such New Investors will, upon delivery to the Company of such signature pages, become parties to, and bound by, the Related Agreements, each to the
same extent as if they had been an Investor at the time of issuance of the first share of Series C Preferred Stock. 
  

 1 

 (c) Status of New Investors. Upon the completion of each Additional Closing as provided in this
Section 1.2, each New Investor will be deemed to be an “Investor” for all purposes of the Related Agreements. 
 2.
Representations and Warranties of the Company. The Company hereby represents and warrants to Investor, that the statements in the following paragraphs of this Section 2 are all true and complete as of May 31, 2008: 
 2.1 Organization, Good Standing and Qualification. The Company is a corporation duly organized, validly existing and in good standing under the
laws of the State of Delaware. The Company is duly qualified to transact business and is in good standing in each jurisdiction in which the failure to so qualify would reasonably be expected to have a material adverse effect on (a) the present
or future business, assets, or operations, of the Company, taken as a whole or (b) the Company’s ability to perform this Agreement or the Related Agreements (as defined below) (a “Material Adverse Effect”).

 2.2 Capitalization and Voting Rights. 
 (a) Authorized Stock. As of June 3, 2008, there are authorized for issuance 40,000,000 shares of common stock, par value $0.0001 (the “Common Stock”) and 19,173,252 shares of
preferred stock, par value $0.0001 (the “Preferred Stock”), of which 5,000,000 shares are designated as Series A Convertible Preferred Stock (“Series A Preferred Stock”), 5,673,252 shares are
designated as Series B Senior Convertible Preferred Stock (“Series B Preferred Stock”), and 8,500,000 shares are designated as Series C Senior Convertible Preferred Stock (“Series C Preferred
Stock”). As of June 3, 2008, the outstanding stock of the Company consists of the following: 
 (i)
Common Stock. Three Million Seven Hundred Fifty Five Thousand (3,755,000) shares of issued and outstanding Common Stock. 
 (ii) Five Million (5,000,000) shares of issued and outstanding Series A Preferred Stock, which shares of Series A Preferred Stock are convertible into 1.680096462 shares of Common Stock upon (x) an
involuntary or voluntary liquidation, dissolution and winding up of the Company, (y) a Deemed Liquidation Event (as such term is defined in the Restated Certificate) or (z) a Qualified IPO (as such term is defined in the Restated
Certificate). 
 (iii) Five Million Six Hundred Seventy Three Thousand Two Hundred and Fifty Two (5,673,252) shares of
issued and outstanding Series B Preferred Stock, which shares of Series B Preferred Stock are convertible into 1.000042304 shares of Common Stock. 
 (iv) Five Million Seven Hundred Sixty Four Thousand Seven Hundred and Seventy Eight (5,764,778) shares of issued and outstanding Series C Preferred Stock. 
 Upon the Closing, the rights, preferences and privileges of each series of Preferred Stock will be as stated in the Restated Certificate and as provided by law.

 (b) Valid Issuance. The outstanding shares of Common Stock and Preferred Stock are all duly and validly authorized and issued,
fully paid and nonassessable. 
 (c) Rights to Acquire. Except for (i) the conversion privileges of the Preferred Stock,
(ii) the rights of first refusal provided in Section 4 of the Investors’ Rights Agreement, (iii)

  

 2 

 
the Five Million (5,000,000) shares of Common Stock reserved for issuance to employees, consultants and/or directors pursuant to the Company’s 2006
Stock Option/Stock Issuance Plan (the “Option Plan”), of which options to purchase an aggregate of Three Million Eight Hundred Thirty-One Thousand Nine Hundred Forty Five (3,831,945) shares of Common Stock are currently
outstanding, (iv) outstanding warrants to purchase Sixty Four Thousand (64,000) shares of Common Stock and (vi) outstanding restricted stock units for the issuance of One Million One Hundred and Four Thousand and Ten
(1,104,010) shares of Common Stock, there are not outstanding any options, warrants, rights (including conversion or preemptive rights) or agreements for the purchase or acquisition from the Company of any shares of its capital stock.

 (d) Voting of Shares. Other than the Voting Agreement, the Company is not a party or subject to any agreement or understanding
and, to the Company’s knowledge, there is no agreement or understanding between any persons and/or entities which affects or relates to the voting or giving of written consents with respect to any security or by a director of the Company.

 (e) Market Stand-Off. To the Company’s best knowledge, all outstanding shares of preferred stock of the Company and all
capital stock of the Company issuable upon the exercise of outstanding employee incentive stock options are subject to a one hundred eighty (180) day “market stand-off” restriction upon an initial public offering by the Company
resulting in at least $20 Million in gross proceeds pursuant to a registration statement filed with the Securities and Exchange Commission (“SEC”) pursuant to the Securities Act of 1933, as amended (the
“Act”). 
 2.3 Subsidiaries. Except for the minority ownership position in Nanotech Catheter Solutions LLC
pursuant to the license agreement with Nanotech Catheter Solutions and the 50% ownership position in Ensysce Biosciences pursuant to the spin off of Ensysce Biosciences and license agreement with Ensysce Biosciences, the Company does not presently
own or control, directly or indirectly, any interest in any other corporation, association, or other business entity. The Company is not a participant in any joint venture, partnership, or similar arrangement. 
 2.4 Authorization. All corporate action on the part of the Company, its officers, directors and stockholders necessary for the authorization,
execution and delivery of this Agreement, the Related Agreements, the performance of all obligations of the Company hereunder and thereunder, and the authorization, sale and issuance of the Shares being sold hereunder, and the Common Stock issuable
upon conversion of the Shares, has been taken or will be taken prior to the Closing. As of the Closing, this Agreement and the Related Agreements constitute valid and legally binding obligations of the Company, enforceable in accordance with their
respective terms, except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to
the availability of specific performance, injunctive relief or other equitable remedies, and (iii) to the extent the indemnification provisions contained in the Related Agreements may be limited by applicable federal or state securities laws.

 2.5 Valid Issuance of Preferred and Common Stock. The Shares that are being purchased by Investor hereunder, when issued, sold and
delivered in accordance with the terms of this Agreement for the consideration expressed herein, will be duly and validly issued, fully paid and nonassessable and will be free of restrictions on transfer, other than restrictions on transfer
(i) under this Agreement, the Investor’s Rights Agreement and the ROFR Agreement, (ii) under applicable state and federal securities laws and (iii) otherwise imposed as a result of actions taken by Investor. The Common Stock
issuable upon conversion of the Shares purchased under this Agreement has been duly and validly reserved for issuance and, upon issuance in accordance with the terms of the Company’s Restated Certificate of Incorporation in the form attached
hereto as Exhibit D (the “Restated Certificate”), will be duly and validly issued, fully paid and nonassessable and will be free of restrictions on transfer, other than restrictions on transfer (i) under this
Agreement, the Investor’s Rights Agreement and the ROFR Agreement, (ii) under applicable state and federal securities laws and (iii) otherwise imposed as a result of actions taken by Investor. 
  

 3 

 2.6 Governmental Consents. No consent, approval, order or authorization of, or registration,
qualification, designation, declaration or filing with, any federal, state or local governmental authority on the part of the Company is required in connection with the consummation of the transactions contemplated by this Agreement and the Related
Agreements, except for such consents, approvals, orders, authorizations, registrations, qualifications, designations, declarations or filings which are not required to be obtained prior to the Closing, and such filings as are required pursuant to
applicable federal and state securities laws and blue sky laws, which filings will be effected within the required statutory period. 
 2.7
Offering. Subject in part to the truth and accuracy of Investor’s representations set forth in Section 3 of this Agreement, the offer, sale and issuance of the Shares as contemplated by this Agreement are exempt from the
registration requirements of the Act, and the qualification or registration requirements of applicable state blue sky laws, as such registration requirements and laws currently exist. 
 2.8 Litigation. There is no action, suit, proceeding or investigation pending or, to the Company’s knowledge, currently threatened in
writing against the Company that questions the validity of this Agreement or the Related Agreements, or the right of the Company to enter into such agreements or to consummate the transactions contemplated hereby and thereby, or that would
reasonably be expected to result in a Material Adverse Effect. The Company is not a party or subject to the provisions of any order, writ, injunction, judgment or decree of any court or government agency or instrumentality. There is no action, suit,
proceeding or investigation by the Company currently pending or that the Company currently intends to initiate. 
 2.9 Proprietary
Information Agreements. Each current employee of the Company has executed a Proprietary Information and Inventions Agreement in substantially the form provided to Investor upon request by Investor. The Company is not aware that any such employee
is in violation thereof. 
 2.10 Compliance with Other Instruments. The Company is not in violation of any provision of its Restated
Certificate or Bylaws nor, to its knowledge, of any instrument, judgment, order, writ, decree or contract, statute, rule or regulation to which the Company is subject and a violation of which would reasonably be expected to have a Material Adverse
Effect. The execution, delivery and performance of this Agreement and the Related Agreements, and the consummation of the transactions contemplated hereby and thereby will not result in any such violation, or be in conflict with or constitute, with
or without the passage of time and giving of notice, either a default under any such provision or an event that results in the creation of any lien, charge or encumbrance upon any assets of the Company or the suspension, revocation, impairment,
forfeiture or nonrenewal of any material permit, license, authorization or approval applicable to the Company, its business or operations or any of its assets or properties. 
 2.11 Agreements; Action. Except for agreements explicitly contemplated hereby, there are no agreements or understandings between the Company and
any of its officers, directors, affiliates or any affiliate thereof (except for transactions with Unidym Acquisition, LLC, of which the Company is a wholly owned subsidiary, and except for quarterly allocations for services performed by Arrowhead)
and except as set forth on Schedule 2.11, 
 (a) there are no agreements, understandings, instruments, contracts, judgments, orders,
writs or decrees to which the Company is a party or by which it is bound that may involve (i) obligations (contingent or otherwise) of, or payments to the Company, in excess of $10,000, other than obligations of, or payments to, the Company
arising from purchase or sale agreements entered into in the ordinary course of business, or (ii) provisions materially restricting the development, manufacture or distribution of the Company’s products or services, and 
  

 4 

 (b) The Company has not (i) declared or paid any dividends or authorized or made any distribution
upon or with respect to any class or series of its capital stock, (ii) incurred any indebtedness for money borrowed or any other liabilities individually in excess of $10,000 or, in the case of indebtedness and/or liabilities individually less
than $10,000, in excess of $25,000 in the aggregate, (iii) made any loans or advances to any person, other than ordinary advances for travel expenses, or (iv) sold, exchanged or otherwise disposed of any of its assets or rights.

 For the purposes of subsections (a) and (b) above, all indebtedness, liabilities, agreements, understandings, instruments and contracts
involving the same person or entity (including persons or entities the Company has reason to believe are affiliated therewith) shall be aggregated for the purpose of meeting the individual minimum dollar amounts of such subsections. 
 2.12 Related-Party Transactions. No employee, officer or director of the Company or member of his or her immediate family is indebted to the
Company, nor is the Company indebted (or committed to make loans or extend or guarantee credit) to any of them. To the best of the Company’s knowledge, other than in Arrowhead Research Corporation, a Delaware corporation
(“Arrowhead”) or in any of Arrowhead’s subsidiaries or Unidym Acquisition, LLC, none of such persons has any direct or indirect ownership interest in any firm or corporation with which the Company is affiliated or with
which the Company has a business relationship, or any firm or corporation that competes with the Company, except that employees, officers or directors of the Company and members of their immediate families may own stock in publicly traded companies
that may compete with the Company. No member of the immediate family of any officer or director of the Company is directly or indirectly interested in any material contract with the Company. 
 2.13 No Undisclosed Liabilities. Except as set forth in the consolidated financial statements of Arrowhead at March 31, 2008 and for the
three months then ended, the Company does not have any liabilities (whether accrued, absolute, unliquidated, contingent or otherwise, whether or not known to the Company, whether due or to become due and regardless of when asserted) arising out of
transactions entered into at or prior to the Closing, or any action or inaction at or prior to the Closing or any state of facts existing at or prior to the Closing other than (i) liabilities and obligations that have arisen after
March 31, 2008 in the ordinary course of business (none of which is material and none of which is a liability resulting from breach of contract, breach of warranty, tort, infringement, claim or lawsuit), (ii) obligations under contracts
and commitments incurred in the ordinary course of business that would not be required to be reflected in financial statements prepared in accordance with generally accepted accounting principles, or (iii) $500,000 transferred by Arrowhead to
the Company to purchase Shares under the same terms and conditions as the New Investors. The Company is not a guarantor or indemnitor of any indebtedness of any other person, firm or corporation. 
 2.14 Permits. The Company has all franchises, permits, licenses and any similar authority necessary for the conduct of its business as now being
conducted by it, except to the extent the lack of which would not reasonably be expected to have a Material Adversely Effect. The Company is not in default under any of such franchises, permits, licenses or other similar authority which would be
reasonably expected to have a Material Adverse Effect. 
 2.15 Environmental and Safety Laws. 
 (a) Except as set forth in Section 2.15(b), to its knowledge, the Company is not in violation of any applicable statute, law or regulation relating
to the environment or occupational health and safety, and, to its knowledge, no material expenditures are or will be required in order to comply with any such existing statute, law or regulation. 
  

 5 

 (b) The US Environmental Protection Agency (the “EPA”) has issued recent
guidance regarding the classification of carbon nanotubes under the Toxic Substances Control Act. The EPA has stated that it now considers carbon nanotubes to be “new chemicals” rather than materials previously listed on the TSCA
Inventory, such as synthetic graphite or other carbon compounds. The Company is in the process of reviewing its compliance with this guidance and has filed paperwork with the EPA. Accordingly, the Company withholds any representation or warranty
regarding the matters disclosed in this Section 2.15(b), including its compliance with the new EPA guidance. 
 2.16 Disclosure.
The Company has fully provided Investor with all the information that Investor has requested in writing for deciding whether to purchase the Shares. Neither this Agreement (including all the exhibits and schedules hereto) nor any other statements or
certificates made or delivered in connection herewith contains any untrue statement of a material fact or omits to state a material fact necessary to make the statements herein or therein not misleading in light of the circumstances under which they
were made. 
 2.17 Registration Rights. Except as provided in the Investors’ Rights Agreement, the Company has not granted or
agreed to grant any registration rights, including piggyback rights, to any person or entity. 
 2.18 Title to Property and Assets.
The property and assets used by the Company in its business are owned by the Company free and clear of all mortgages, liens, loans and encumbrances, except for (i) statutory liens for the payment of current taxes that are not yet delinquent and
(ii) for liens, encumbrances and security interests that arise in the ordinary course of business and minor defects in title, none of which, individually or in the aggregate, would reasonably be expected to have a Material Adverse Effect. With
respect to the property and assets it leases, the Company is in compliance with such leases and, to its knowledge, holds a valid leasehold interest free of any liens, claims or encumbrances, subject to clauses (i)-(ii) of the foregoing sentence,
except to the extent the failure to be in compliance or hold a valid leasehold interest would not reasonably be expected to have a Material Adverse Effect. 
 2.19 Labor Agreements and Actions. The Company is not bound by or subject to any contract, commitment or arrangement with any labor union, and no labor union has requested or, to the Company’s knowledge,
has sought to represent any of the employees, representatives or agents of the Company. There is no strike or other labor dispute involving the Company pending, or to the Company’s knowledge, threatened in writing, that would reasonably be
expected to have a Material Adverse Effect, nor is the Company aware of any labor organization activity involving its employees. The Company is not aware that any officer or key employee, or that any group of key employees, intends to terminate
their employment with the Company, nor does the Company have a present intention to terminate the employment of any of the foregoing. The employment of each officer and employee of the Company is terminable at the will of the Company. The Company is
not a party to or bound by any currently effective employment contract, deferred compensation agreement, bonus plan, incentive plan, profit sharing plan, retirement agreement or other employee compensation agreement, except that pursuant to his
employment arrangement, the CEO of the Company is entitled to certain severance payments and acceleration of options if he is terminated or constructively terminated without cause. To its knowledge, the Company has complied in all material respects
with all applicable state and federal equal employment opportunity and other laws related to employment. 
 2.20 Brokers Fees. The
Company expects to pay third-party finders or advisors finder’s fees (in cash and/or equity) for Shares placed by such third party. For the sake of clarity, no finder’s fees will be paid for Shares not placed by a third-party finder or
advisor. 
  

 6 

 2.21 Intellectual Property. To its knowledge, the Company has rights to all intellectual property
it needs to operate its business as currently conducted, other than intellectual property that it reasonably believes is invalid or it can obtain rights to through a license or cross-licensing arrangement. 
 2.22 Tax Returns and Payments. There are no federal, state, county, local or foreign taxes dues and payable by the Company which have not been
timely paid. There are no accrued and unpaid federal, state, country, local or foreign taxes of the Company which are due, whether or not assessed or disputed. There have been no examinations or audits of any tax returns or reports by any
applicable federal, state, local or foreign governmental agency. The Company has duly and timely filed all federal, state, county, local and foreign tax returns required to have been filed by it and there are in effect no waivers of applicable
statutes of limitations with respect to taxes for any year. 
 2.23 Insurance. The Company has in full force and effect fire and
casualty insurance policies with extended coverage, sufficient in amount (subject to reasonable deductions) to allow it to replace any of its properties that might be damaged or destroyed. 
 2.24 ERISA. The Company has made all required contributions and has no liability to any such employee benefit plan, other than liability for
health plan continuation coverage described in Part 6 of Title I(B) of Employee Retirement Income Security Act of 1974, as amended, and has complied in all material respects with all applicable laws for any such employee benefit plan.

 3. Representations and Warranties of Investor. Investor hereby represents, warrants and covenants to the Company that: 

3.1 Authorization. Investor has full power and authority to enter into this Agreement and the Related Agreements to which it is a party, and
each such agreement constitutes its valid and legally binding obligation, enforceable in accordance with its terms except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application
affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies, and (iii) to the extent the indemnification provisions
contained in the Related Agreements may be limited by applicable federal or state securities laws. 
 3.2 Purchase Entirely for Own
Account. This Agreement is made with Investor in reliance upon Investor’s representation to the Company, which by Investor’s execution of this Agreement, Investor hereby confirms that the Shares will be acquired for investment for
Investor’s own account, not as a nominee or agent, and not with a view to the resale or distribution of any part thereof, and that Investor has no present intention of selling, granting any participation in or otherwise distributing the same.
By executing this Agreement, Investor further represents that Investor does not have any contract, undertaking, agreement or arrangement with any person to sell, transfer or grant participations to such person or to any third person, with respect to
any of the Shares. 
 3.3 Disclosure of Information. Investor believes it has received all the information it considers necessary or
appropriate for deciding whether to purchase the Shares. Investor further represents that it has had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the offering of the Shares and the
business, properties, prospects and financial condition of the Company. The foregoing, however, does not limit or modify the representations and warranties of the Company in Section 2 of this Agreement or the right of Investor to rely thereon.

 3.4 Investment Experience. Investor is an investor in securities of companies in the development stage and acknowledges that
he/she/it is able to bear the economic risk of its investment, and has such knowledge and experience in financial or business matters that it is capable of evaluating the merits and risks of the investment in the Shares. If other than an individual,
Investor also represents it has not been organized for the purpose of acquiring the Shares. 
  

 7 

 3.5 Accredited Investor. Investor is an “accredited investor” within the meaning of SEC
Rule 501 of Regulation D and has reviewed Schedule 3.5 before making this representation to the Company. All of the information in the Investor Questionnaire delivered by Investor to the Company in connection with Investor’s purchase of the
Shares remains complete, true and correct as of the Closing or the Additional Closing, as applicable. 
 3.6 Restricted Securities.
Investor understands that the Shares it is purchasing are characterized as “restricted securities” under the federal securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering, and
that under such laws and applicable regulations, such Shares may be resold without registration under the Act only in certain limited circumstances. In the absence of an effective registration statement covering the Shares or an available exemption
from registration under the Act, the Shares (and any Common Stock issued on conversion of the Shares) must be held indefinitely. 
 3.7
No Brokers. Investor has not taken any action which would give rise to any claim by any person for brokerage commissions, finder’s fees or similar payments relating to this Agreement or the transactions contemplated hereby. 

3.8 Legends. It is understood that the certificates evidencing the Shares may bear one or all of the following legends: 
 (a) “These securities have not been registered under the Securities Act of 1933, as amended. They may not be sold, offered for sale, pledged or
hypothecated in the absence of a registration statement in effect with respect to the securities under such Act or an opinion of counsel satisfactory to the Company that such registration is not required or unless sold pursuant to Rule 144 of such
Act.” 
 (b) Legends required to indicate that the Shares are subject to the terms of the Investors Rights Agreement and ROFR
Agreement. 
 (c) Any legend required by applicable laws. 
 4. Conditions to Investor’s Obligations at Closing. The following conditions must be satisfied by the Company, unless waived by Investor, in Investor’s sole and absolute discretion. 
 4.1 Representations and Warranties. The representations and warranties of the Company contained in Section 2 shall be true on and as of the
Closing with the same effect as though such representations and warranties had been made on and as of the date of the Closing. 
 4.2
Performance. The Company shall have performed and complied with all agreements, obligations and conditions contained in this Agreement that are required to be performed or complied with by it on or before the Closing. 
 4.3 Qualifications. All authorizations, approvals or permits, if any, of any governmental authority or regulatory body of the United States or of
any state that are required in connection with the lawful issuance and sale of the Shares pursuant to this Agreement shall be duly obtained and effective, other than such authorizations, approvals or permits or other filings which may be timely made
after such issuance and sale of the Shares. 
  

 8 

 4.4 Proceedings and Documents. All corporate and other proceedings in connection with the
transactions contemplated at the Closing and all documents incident thereto shall be reasonably satisfactory in form and substance to Investor, and Investor shall have received all such counterpart original and certified or other copies of such
documents as may be reasonably requested. 
 4.5 General. The holders of Common Stock and/or Preferred Stock shall have amended any
other agreement or arrangement, or given any further consent required to allow the Company to execute and perform this Agreement and the Related Agreements. 
 5. Conditions to the Company’s Obligations at Closing. The following conditions must be satisfied by Investor, unless waived in writing by the Company, in the Company’s sole and absolute discretion.

 5.1 Representations and Warranties. The representations and warranties of the Investor contained in Section 3 shall be true
on and as of the Closing or the Additional Closing (as applicable) with the same effect as though such representations and warranties had been made on and as of the date of such closing. 
 5.2 Payment of the Purchase Price. Investor shall have delivered to the Company the purchase price for the Shares. 
 5.3 Securities Exemptions. The offer and sale of the Shares to Investor pursuant to this Agreement shall be exempt from the registration
requirements of the Act, the qualification requirements of the California General Corporation Law and the registration and/or qualification requirements of all other applicable state securities laws. 
 5.4 Proceedings and Documents. All corporate and other proceedings in connection with the transactions contemplated at the Closing or the
Additional Closing (as applicable) and all documents incident thereto shall be reasonably satisfactory in form and substance to the Company, and the Company shall have received all such counterpart original and certified or other copies of such
documents as may be reasonably requested. 
 5.5 Investors’ Rights Agreement. The Investor shall have executed and delivered a
counterpart signature page to the Investors’ Rights Agreement. 
 5.6 ROFR Agreement. The Investor shall have executed and
delivered a counterpart signature page to the ROFR Agreement. 
 5.7 Voting Agreement. The Investor shall have executed and delivered
a counterpart signature page to the Voting Agreement. 
 5.8 General. The holders of Common Stock and/or Preferred Stock shall have
amended any other agreement or arrangement, or given any further consent required to allow the Company to execute and perform this Agreement and the Related Agreements. 
 6. Miscellaneous. 
 6.1 Survival. The warranties, representations and covenants of the Company
and Investor contained in or made pursuant to this Agreement shall survive the execution and delivery of this Agreement and the Closing or the Additional Closing (as applicable) and shall in no way be affected by any investigation of the subject
matter thereof made by or on behalf of Investor or the Company. 
  

 9 

 6.2 Successors and Assigns. Except as otherwise provided herein, the terms and conditions of this
Agreement shall inure to the benefit of, and be binding upon, the respective successors and assigns of the parties (including transferees of any Shares). Nothing in this Agreement, express or implied, is intended to confer upon any party, other than
the parties hereto or their respective successors and assigns, any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. 
 6.3 Governing Law. This Agreement shall be governed by and construed under the laws of the State of California as applied to agreements among
California residents entered into and to be performed entirely within California, except with respect to conflict of laws. 
 6.4 Titles
and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement. 
 6.5 Notices. All notices required or permitted hereunder shall be in writing and shall be deemed effectively given: (i) upon personal
delivery to the party to be notified, (ii) when sent by confirmed telex or facsimile if sent during normal business hours of the recipient, if not, then on the next business day; (iii) five (5) days after having been sent by
registered or certified mail, return receipt requested, postage prepaid; or (iv) one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. All
communications shall be sent to the address as set forth on the signature page hereof or at such other address as such party may designate by ten (10) days’ advance written notice to the other parties hereto. 
 6.6 Responsibility for Brokers Fees. Investor indemnifies and holds harmless the Company from any liability for any commission or compensation in
the nature of a finders’ fee (and the costs and expenses of defending against such liability or asserted liability) for which Investor or any of its officers, partners, employees or representatives is responsible. The Company indemnifies and
holds harmless Investor from any liability for any commission or compensation in the nature of a finders’ fee (and the costs and expenses of defending against such liability or asserted liability) for which the Company or any of its officers,
employees or representatives is responsible. 
 6.7 Aggregation of Stock. All issued and outstanding shares of the Series C Preferred
Stock and Common Stock issued upon conversion thereof held or acquired by affiliated entities or persons shall be aggregated together for the purpose of determining the availability of any rights under this Agreement. 
 6.8 Amendments and Waivers. Any term of this Agreement may be amended, and the observance of any term of this Agreement may be waived (either
generally or in a particular instance and either retroactively or prospectively), only with the written consent of the Company and Investor. 
 6.9 Severability. If one or more provisions of this Agreement are held to be unenforceable under applicable law, such provision shall be excluded from this Agreement and the balance of the Agreement shall be interpreted as if such
provision were so excluded and shall be enforceable in accordance with its terms. 
 6.10 Entire Agreement. This Agreement and the
documents referred to herein constitute the entire agreement among the parties, and this Agreement supersedes all prior written and oral agreements, and all contemporaneous oral agreements, relating to the subject matter hereof. 
 6.11 Counterparts; Facsimile/PDF Signatures. This Agreement may be executed in two or more counterparts, and by facsimile signatures or portable
document format (.pdf or similar format), each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 
  

 10 

 [SIGNATURE PAGE FOLLOWS] 
  

 11 

 [Company Signature Page to Subscription Agreement] 
  

									
	Dated:	 	
                                         
                   	 		 	COMPANY:
				
		 		 		 	 UNIDYM, INC.
 a Delaware
corporation

					
		 		 		 	By:	 	 Arthur L. Swift

		 		 		 		 	CEO & President
					
		 		 		 	Address:	 	1430 Obrien Drive
		 		 		 		 	Menlo Park, CA 94025

 [Investor Signature Page to Subscription Agreement] 
 I HEREBY REPRESENT THAT I HAVE READ AND UNDERSTOOD THE SUBSCRIPTION AGREEMENT. 
 Dated:
                                         
        
 Subscription: I hereby subscribe for the following number of Shares at the Purchase Price
indicated: 
 Total Number of Shares:
                                        

 Total Purchase Price ($1.80 Per Share):
                                        

  

	
	
                                         
                                         
                                         
                                         
                
	Please print the exact name(s) in which the Shares will be issued
	
	Print Name of Signer:                                 
                                         
                                         
                             
	
	Signature:                                      
                                         
                                         
                                         
   
	
	Title of Signer (if purchaser is an entity):                          
                                         
                                         
    
	
	Social Security # or Tax Id#:                              
                                         
                                         
                    
	
	Address:                                      
                                         
                                         
                                         
     
	
	
                                         
                                         
                                         
                                         
                    
	
	City, State & Zip:                                 
                                         
                                         
                                     
	
	Phone:                                      
                                         
                                         
                                         
           
	
	Facsimile:                                      
                                         
                                         
                                         
   
	
	Email:                                      
                                         
                                         
                                         
           

 Exhibit A 
 Amended and Restated Investors’ Rights Agreement 

 Exhibit B 
 Amended and Restated Right of First Refusal and Co-Sale Agreement 

 Exhibit C 
 Amended and Restated Voting Agreement 

 Exhibit D 
 Restated Certificate of Incorporation 

 Schedule 3.5 
 Qualification as an Accredited Investors 
 To qualify as an Accredited Investor one of the following must be true.
Contact the Company if none is applicable): 
 A natural person whose net worth (or joint net worth with my spouse) is in excess of
$1,000,000 as of the date hereof. 
 A natural person who had an individual income in excess of $200,000 in each of the two most recent years
or joint income with that person’s spouse in excess of $300,000 in each of those years and has a reasonable expectation of reaching the same income level in the current year. 
 A trust with total assets in excess of $5,000,000, not formed for the specific purpose of investing in the Interest, whose purchases are directed by a
“sophisticated person” as described in Rule 506(b)(2)(ii) of the Act. 
 A “bank,” “savings and loan
association,” or “insurance company” as defined in the Act. 
 An “employee benefit plan” as defined in the Employee
Retirement Income Security Act of 1974 which has total assets in excess of $5,000,000. 
 A Plan whose investment decisions, including the
decision to subscribe for the Interest, are made solely by (i) a “plan fiduciary” as defined in the Employee Retirement Income Security Act of 1974, which includes a bank, a savings and loan association, an insurance company or a
registered investment adviser, or (ii) an “accredited investor” as defined under Rule 501(a) of the Act. 
 A broker/dealer
registered pursuant to Section 15 of the Securities Exchange Act of 1934. 
 A “private business development company” as
defined in the Investment Advisers Act of 1940. 
 An investment company registered under, or a “business development company” as
defined in, the Investment Company Act of 1940. 
 A Small Business Investment Company licensed by the U.S. Small Business Administration
under the Small Business Investment Act of 1958. 
 A plan established and maintained by a state, its political subdivisions, or any agency or
instrumentality of a state or its political subdivisions, for the benefit of its employees and having total assets in excess of $5,000,000. 
 Any organization described in Section 501(c)(3) of the Internal Revenue Code, corporation, Massachusetts or similar business Trust, or Company, not formed for the specific purpose of investing in the Interest and having total assets in
excess of $5,000,000. 
 Any entity in which all of the equity owners are “accredited investors.”

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00143-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00143-of-00352.parquet"}]]